Biotech initiates partnership search immediately
The time is different now in terms of winning approval for new drugs to treat obesity, says Saniona CEO Jørgen Drejer. The international community has admitted that we are in the midst of an epidemic, he believes.
BY HENRIK TÜCHSEN
Sweden-based biotech Saniona, which focuses on developing drugs against neurological diseases, will begin looking for a partner for its newly acquired obesity candidate, tesofensine, as early as next week.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
“I‘m certainly not bitter, but maybe a bit disappointed”
For abonnenter
